News
In this piece, we will look at the stocks Jim Cramer recently discussed.
While S&P 500 is at its all-time high, Danaher is still ~34% below its peak from late 2021. The company was beleaguered with ...
(Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending ...
Danaher Corp soared in the stock market after announcing better-than-expected second-quarter results. The company reported ...
Danaher reported generating $1.1 billion in free cash flow during the quarter, with adjusted diluted net earnings per share increasing by approximately 5% year-over-year. This financial strength ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Explore more
Danaher Corporation thrives on bioprocessing demand and diagnostics resilience. Click for why, with solid execution and 80% ...
Q2 2025 Earnings Call Transcript July 22, 2025 Danaher Corporation beats earnings expectations. Reported EPS is $1.8, expectations were $1.64. Margaux: My name is Margaux, and I’ll be your conference ...
Montag A & Associates Inc. took a step back from Danaher, slashing their stake by a hefty 28.6%. The firm sold 8,037 shares, ...
Danaher Corp (DHR) reports robust free cash flow and bioprocessing growth, while navigating global trade tensions and Life ...
Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...
Danaher (NYSE:DHR) reported its second-quarter 2025 results on July 22, 2025, with sales of $5.9 billion and core revenue growth of 1.5% year over year. Adjusted diluted EPS grew 5% to $1.80, free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results